Diabetes Care
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by McMahon, G. T.
Right arrow Articles by DiCarli, M. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by McMahon, G. T.
Right arrow Articles by DiCarli, M. F.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Diabetes Care 28:1145-1150, 2005
© 2005 by the American Diabetes Association, Inc.

Pathophysiology/Complications
Original Article

Effect of a Peroxisome Proliferator–Activated Receptor-{gamma} Agonist on Myocardial Blood Flow in Type 2 Diabetes

Graham T. McMahon, MB, BCH1, Jorge Plutzky, MD2, Edouard Daher, MD3, Tammy Bhattacharyya, MD4, George Grunberger, MD4 and Marcelo F. DiCarli, MD5

1 Division of Endocrinology, Diabetes, and Hypertension, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts
2 Department of Cardiovascular Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts
3 Division of Cardiology, Wayne State University School of Medicine, Detroit, Michigan
4 Division of Endocrinology, Diabetes, and Metabolism, Wayne State University School of Medicine, Detroit, Michigan
5 Department of Nuclear Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts

Address correspondence and reprint requests to Marcelo F. DiCarli, MD, Brigham and Women’s Hospital, Division of Nuclear Medicine, 75 Francis St., Boston, MA 02115. E-mail: mdicarli{at}partners.org

OBJECTIVE—The relationship between coronary endothelial function and insulin resistance remains speculative. We sought to determine whether pioglitazone, an insulin-sensitizing peroxisome proliferator–activated receptor (PPAR)-{gamma} agonist, improves cardiac endothelial function in individuals with type 2 diabetes.

RESEARCH DESIGN AND METHODS—Sixteen subjects with insulin-treated type 2 diabetes and without overt cardiovascular disease were randomly assigned to receive either 45 mg of pioglitazone or matching placebo for 3 months. Rest and adenosine-stimulated myocardial blood flow (MBF) were quantified with [13N]ammonia and positron emission tomography at baseline and study conclusion.

RESULTS—After 3 months, HbA1c levels dropped by 0.68% in the pioglitazone group and increased by 0.17% in the placebo group (P = 0.009 for difference between groups). Triglyceride (–93 vs. –39 mg/dl, P = 0.026) and HDL concentrations (+4.8 vs. –6.0 mg/dl, P = 0.014) improved significantly in the pioglitazone group compared with placebo. Despite these favorable changes, there was no demonstrable change in baseline MBF (–0.05 ± 0.24 vs. –0.09 ± 0.24 ml · min–1 · g–1, P = 0.45), adenosine-stimulated MBF (0.10 ± 0.75 vs. 0.14 ± 0.31 ml · min–1 · g–1, P = 0.25), or coronary flow reserve (0.45 ± 1.22 vs. 0.35 ± 0.72 ml · min–1 · g–1, P = 0.64) after 12 weeks of exposure to pioglitazone or placebo, respectively. Regression analysis revealed that lower glucose concentration at the time of the study was associated with higher coronary flow reserve (P = 0.012).

CONCLUSIONS—Pioglitazone treatment for 12 weeks in subjects with insulin-requiring type 2 diabetes had no demonstrable effect on coronary flow reserve despite metabolic improvements. Higher ambient glucose levels contribute to impaired vascular reactivity in individuals with diabetes.

Abbreviations: MBF, myocardial blood flow • PET, positron emission tomography • PPAR, peroxisome proliferator–activated receptor


Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 J Am Coll CardiolHome page
R. P. Naoumova, H. Kindler, L. Leccisotti, M. Mongillo, M. T. Khan, C. Neuwirth, M. Seed, P. Holvoet, J. Betteridge, and P. G. Camici
Pioglitazone Improves Myocardial Blood Flow and Glucose Utilization in Nondiabetic Patients With Combined Hyperlipidemia: A Randomized, Double-Blind, Placebo-Controlled Study
J. Am. Coll. Cardiol., November 20, 2007; 50(21): 2051 - 2058.
[Abstract] [Full Text] [PDF]

Home page
 Vasc MedHome page
A. S. Kelly, A. M. Thelen, D. R. Kaiser, J. M. Gonzalez-Campoy, and A. J. Bank
Rosiglitazone improves endothelial function and inflammation but not asymmetric dimethylarginine or oxidative stress in patients with type 2 diabetes mellitus
Vascular Medicine, November 1, 2007; 12(4): 311 - 318.
[Abstract] [PDF]

Home page
 British Journal of Diabetes & Vascular DiseaseHome page
P. Raggi and A. Bellasi
Review: Imaging to assess effect of medical therapy in patients with diabetes mellitus
The British Journal of Diabetes & Vascular Disease, July 1, 2007; 7(4): 157 - 164.
[Abstract] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
H. V. Joffe, R. Y. Kwong, M. D. Gerhard-Herman, C. Rice, K. Feldman, and G. K. Adler
Beneficial Effects of Eplerenone Versus Hydrochlorothiazide on Coronary Circulatory Function in Patients with Diabetes Mellitus
J. Clin. Endocrinol. Metab., July 1, 2007; 92(7): 2552 - 2558.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 2005 by the American Diabetes Association.